Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
Background: Fingolimod was the first oral therapy approved for treating relapsing-remitting multiple sclerosis (RRMS) in 2010. This open-label study evaluated the safety and efficacy of fingolideR, 0.5 mg in Iranian MS patients during one-year follow-up. Methods: A multicenter, open-label, longitudi...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Babol University of Medical Sciences
2021-04-01
|
Series: | Caspian Journal of Internal Medicine |
Subjects: | |
Online Access: | http://caspjim.com/article-1-2280-en.html |